A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group With a Crossover Confirmation Period Study of RWJ-333369 for the Treatment of Postherpetic Neuralgia.
Phase of Trial: Phase II
Latest Information Update: 04 May 2018
At a glance
- Drugs Carisbamate (Primary)
- Indications Neuropathic pain; Postherpetic neuralgia
- Focus Therapeutic Use
- Sponsors Janssen Research & Development; SK Life Science
- 15 Jun 2012 Drug company SK Life Science added to the associations field as reported by ClinicalTrials.gov record.
- 29 Jan 2009 Actual patient numbers (91) added as reported by ClinicalTrials.gov.
- 29 Jan 2009 Actual end date (Jun 2008) added as reported by ClinicalTrials.gov.